Monopar Therapeutics (NASDAQ:MNPR) Price Target Raised to $40.00

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) had its price objective raised by HC Wainwright from $22.00 to $40.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. HC Wainwright's target price indicates a potential upside of 18.80% from the stock's previous close.

MNPR has been the subject of several other reports. Piper Sandler initiated coverage on shares of Monopar Therapeutics in a research report on Friday, January 10th. They issued an "overweight" rating and a $72.00 target price for the company. Rodman & Renshaw initiated coverage on shares of Monopar Therapeutics in a research note on Friday, October 11th. They issued a "buy" rating and a $50.00 price target for the company.

Monopar Therapeutics Stock Performance

MNPR stock traded up $1.99 during midday trading on Wednesday, reaching $33.67. 76,571 shares of the company's stock traded hands, compared to its average volume of 50,436. The company has a 50-day moving average price of $23.48 and a two-hundred day moving average price of $12.00. Monopar Therapeutics has a 52 week low of $1.54 and a 52 week high of $38.50. The firm has a market capitalization of $205.39 million, a PE ratio of -17.09 and a beta of 1.23.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last released its quarterly earnings results on Friday, November 8th. The company reported ($0.37) EPS for the quarter, beating analysts' consensus estimates of ($0.46) by $0.09. As a group, analysts predict that Monopar Therapeutics will post -1.65 EPS for the current fiscal year.

Insider Activity

In other Monopar Therapeutics news, CFO Karthik Radhakrishnan acquired 1,550 shares of the business's stock in a transaction on Monday, October 28th. The shares were acquired at an average price of $16.25 per share, for a total transaction of $25,187.50. Following the completion of the acquisition, the chief financial officer now owns 1,550 shares in the company, valued at $25,187.50. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 34.90% of the company's stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.